Related Experiment Video

Updated: Jun 5, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Noncompliance with medications in pediatric patients after living-donor liver transplantation

Y Masuda1, A Mita, Y Ohno

  • 1Division of Transplantation, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.

Transplantation Proceedings
|December 21, 2010
PubMed

Insights

Noncompliance with immunosuppressant therapy after living-donor liver transplantation (LDLT) is uncommon in pediatric patients. Interventions can improve adherence, and noncompliance did not lead to graft loss in this study.

Area of Science:

  • Transplantation Medicine
  • Pediatric Gastroenterology
  • Immunology

Background:

  • Noncompliance with immunosuppressant therapy is a significant risk factor for graft rejection in liver transplant recipients.
  • Long-term adherence is crucial for maintaining graft survival after liver transplantation.
  • Understanding noncompliance patterns in living-donor liver transplantation (LDLT) is essential for improving patient outcomes.

Purpose of the Study:

  • To review and describe the characteristics of patient noncompliance following living-donor liver transplantation (LDLT).
  • To identify the prevalence and clinical features of noncompliance in pediatric LDLT recipients.

Main Methods:

  • Retrospective study of pediatric patients (<18 years) surviving over 5 years post-LDLT.
  • Identification and analysis of clinicopathologic characteristics of noncompliant patients.

Main Results:

  • Out of 108 pediatric survivors (>5 years post-LDLT), 6 female patients (5.6%) exhibited noncompliance.
  • Noncompliance occurred at a median age of 18 years, 8 years post-transplantation.
  • Increased immunosuppression improved liver function in noncompliant patients; 33% experienced recurrence, but no graft or patient loss occurred.

Conclusions:

  • The prevalence of noncompliance in pediatric LDLT recipients is relatively low.
  • Liver dysfunction due to noncompliance can be effectively managed with increased immunosuppression.
  • Early intervention and monitoring are key to managing noncompliance and ensuring long-term graft survival.
Abstract

More Related Videos

Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation08:39

Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation

Published on: November 7, 2020

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...